AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 152 filers reported holding AKERO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 1.85 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,774,131 | +15.7% | 252,553 | +6.8% | 0.00% | 0.0% |
| Q2 2023 | $11,039,804 | +1446.9% | 236,449 | +1167.6% | 0.00% | – |
| Q1 2023 | $713,664 | -93.6% | 18,653 | -90.8% | 0.00% | -100.0% |
| Q4 2022 | $11,125,934 | +37.4% | 203,028 | -14.7% | 0.00% | 0.0% |
| Q3 2022 | $8,100,000 | +5300.0% | 237,886 | +2147.4% | 0.00% | – |
| Q1 2022 | $150,000 | -32.1% | 10,585 | +1.5% | 0.00% | – |
| Q4 2021 | $221,000 | -15.0% | 10,429 | -10.5% | 0.00% | – |
| Q3 2021 | $260,000 | +4.4% | 11,656 | +16.2% | 0.00% | – |
| Q2 2021 | $249,000 | – | 10,029 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $168,435,000 | 13.00% |
| venBio Partners LLC | 2,444,311 | $63,063,000 | 5.57% |
| Versant Venture Management, LLC | 777,727 | $20,065,000 | 2.08% |
| Vivo Capital, LLC | 633,426 | $16,342,000 | 0.73% |
| Redmile Group, LLC | 2,322,557 | $59,922,000 | 0.73% |
| Boxer Capital, LLC | 831,495 | $21,453,000 | 0.69% |
| Integral Health Asset Management, LLC | 85,000 | $2,193,000 | 0.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 35,179 | $908,000 | 0.53% |
| HighVista Strategies LLC | 27,739 | $716,000 | 0.46% |
| Cormorant Asset Management, LP | 742,549 | $19,158,000 | 0.46% |